Osteopetrosis

View Details
Status
Done
logo
Parent item

General

  • Definition: a group of rare bone disorders, within the family of sclerosing bone dysplasias, characterized by reduced osteoclastic bone resorption that results in a high bone mass.
  • Derived from the Greek words for "bone" ("osteo") and "stone" ("petros")

Numbers

  • Incidence:
    • 1:200,000 for autosomal-recessive osteopetrosis
    • 1:20,000 for autosomal-dominant osteopetrosis

Subtype

  • “malignant” autosomal recessive infantile form
    • Fatal first year of life
  • Osteopetrosis has for decades been categorized descriptively by its clinical severity and inheritance pattern into a , a “benign” adult autosomal-dominant form (which can be severe), and an intermediate form

Pathophysiology

  • Molecules affecting osteoclast differentiation and function.
    • The binding of receptor activator of nuclear factor κ-B (RANK) ligand (RANKL) produced by osteoblasts to RANK on osteoclast precursors induces osteoclast differentiation;
    • in animals with defects in these genes, no osteoclasts are observed.
    • In disorders of acidification—there are no primary defects in differentiation reduced osteoclastic bone resorption that results in a high bone mass.
      • including defects in carbonic anhydrase II (CAII), the osteoclast-specific proton pump (encoded by TCIRG1, also termed ATP6i), and the gene encoding a chloride channel (CLCN7)
  • Normal bone resorption by Osteoclasts:
      1. Differentiation from granulocyte-macrophage precursors → osteoclast
      1. Osteoclast attachment to bone
      1. Creation of a ruffled border (resorptive surface)
      1. Acidification of bone to dissolve and digest the mineral matrix
          • Generation of protons by carbonic anhydrase II (CAII)
          • Transport of protons through the ruffled border by a vacuolar proton pump
          • Maintenance of electroneutrality in the ruffled border by chloride exchange
  • Defects in Osteopetrosis:
    • Loss-of-function mutations impairing the acidification process through trafficking and/or fusion of lysosome-related organelles to the ruffled border
      • eg of mutations:
        • Osteoclast vacuolar proton pump (TCIRG1, MIM 604592)
        • H+-Cl− exchange transporter 7 (CLCN7, MIM 602727)
          • Account for nearly 70% of autosomal-recessive osteopetrosis
        • CAII enzyme (MIM 611492)
        • Stabilizing β-subunit of the H+-Cl− exchange transporter 7 (OSTM1, MIM 607649)
        • Lysosome-associated protein involved in vesicular trafficking (PLEKHM1, MIM 611466)
  • Osteoclast-Poor Forms of Autosomal Recessive Osteopetrosis:
    • Mutations in tumor necrosis factor ligand superfamily member 11 (TNFSF11, MIM 602642)
    • Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A, MIM 603499)
    • Interference with receptor activator of nuclear factor κ-B receptor and ligand signaling pathway
    • Impact on osteoblast activation of osteoclastogenesis
  • Due to poor bone reabsorption and net bone formation → Rather than conferring strength, the overly dense bone architecture forms a structural brittle bone that predisposes to fracture → give rise to skeletal deformity and dental abnormalities
    • Can interfere with
      • Mineral homeostasis expansion of bone into marrow cavities
        • Manifest as profound anaemia, bleeding, frequent infections, and hepatosplenomegaly from extramedullary hematopoiesis.
      • Cranial nerve foramina
        • The latter can lead to blindness, deafness, and nerve palsies
        •  
notion image
flowchart LR A[Poor bone resorption and<br>net bone formation] B[Overly dense<br>bone architecture] C[Structural brittle bone] D[Skeletal deformity<br>and dental abnormalities] E[Interference with<br>mineral homeostasis] F[Expansion of bone<br>into marrow cavities] G[Profound anaemia, bleeding,<br>frequent infections,<br>hepatosplenomegaly from<br>extramedullary<br>hematopoiesis] H[Interference with cranial<br>nerve foramina] I[Blindness, deafness,<br>and nerve palsies] A --> B B --> C C --> D D --> E E --> F F --> G E --> H H --> I

Radiology

  • Skeletal survey is sufficient to make the diagnosis.
    • Because of the wide gamut of pathognomonic radiographic features of osteopetrosis,
    • Parallel bands of dense bone can give the appearance of “bone-within-bone” or “endobones.”
      • Seen most often in the
        • pelvis,
        • long bones,
          • Club-shaped flaring of the metaphyses of long bones with cortical thinning (Erlenmeyer flask bone deformity) and transverse metaphyseal lucent bands reflect a failure of metaphyseal remodeling but are not exclusive to osteopetrosis
        • phalanges,
        • Vertebrae
          • Vertebrae can also be uniformly dense or take on a “sandwich vertebrae” or “rugger-jersey” appearance (when a normal-appearing vertebral midbody is sandwiched between dense bands along the superior and inferior endplates).
        • Evidence of new or healing fractures may be found, and skull changes can include calvarial and basilar thickening as well as poor sinus development.
        •  
Left: Vertebral midbodies sandwiched between dense bands along superior and inferior endplates (“sandwich vertebrae”). 
Right: Bone-within-bone appearance.
Left: Vertebral midbodies sandwiched between dense bands along superior and inferior endplates (“sandwich vertebrae”).
Right: Bone-within-bone appearance.
 
  • Neurology and neurosurgery symptoms
    • Most prevalent neurologic complications of osteopetrosis are the compressive neuropathies that stem from progressive constriction of cranial foramina and/or the failure of these foramina to enlarge proportionately with growth.
      • Autosomal-recessive osteopetrosis
        • The optic nerve most affected
          • Optic nerve decompression (17, 25) and optic nerve sheath fenestration (44) in the appropriate clinical settings have been demonstrated to improve visual function and may better preserve visual acuity if performed early (45), although it is important to note that such positive outcomes are not universal (28, 46–48) and can be difficult to achieve in very young patients.
      • autosomal-dominant CLCN7-deficient osteopetrosis
        • most frequent cranial nerve deficit in is the facial nerve followed by the acoustic nerve, although any of cranial nerves I through VIII can be involved
        • Many of the cranial palsies can be subclinical (41) and are detected only on careful evaluation or after they have progressed.
          • Successful results have also been reported to follow decompression of the facial and acoustic nerves
    • Less commonly reported are the consequences of calvarial thickening reducing cranial capacity, which can include increased ICP, posterior fossa crowding, cerebellar tonsillar herniation, and hydrocephalus
    • Cerebrovascular stenosis and occlusion
    • Craniosynostosis
    • Arnold–Chiari I malformation
    • Neurologic disease is associated with some specific genetic mutations.
      • Developmental delay or regression, unexplained seizures, and neuroradiologic findings should alert to the possibility of an OSTM1 mutation.
      • The cognitive defects of CAII deficiency are more variable, but the calcifications involving the basal ganglia, thalami, and/or gray-matter junction are almost always present

Other associated complication

Subspecialty
Complication
Endocrinology
Osteopetrorickets
Hypocalcemia
Ophthalmology
Papilledema
Ptosis
Strabismus
Paralysis of extraocular muscles
Optic nerve atrophy
Exophthalmos
Nystagmus
Retinal degeneration
Tearing (from nasolacrimal duct obstruction)
Dentistry
Delay/failure of tooth eruption
Malformed crowns/roots
Periodontal ligament defects
Odontoma
Tooth agenesis
Enamel hypoplasia
Tooth decay/caries
Thickened lamina dura
Osteomyelitis (most frequently of the mandible)
Orthopedics
Skeletal deformities
Scoliosis
Spondylolisthesis
Fractures (particularly of the long bones)
Delayed union/nonunion
Degenerative arthritis
Spondylolysis
Neurology/Neurosurgery
Compressive cranial neuropathies (often optic and facial nerves, but can involve any of cranial nerves I-VIII)
Increased intracranial pressure
Craniosynostosis
Arnold-Chiari I malformation
Neuromuscular scoliosis
Developmental delay/regression, seizures (OSTM1 mutation)
Calcifications of the basal ganglia, thalami (CAII deficiency)
Hydrocephalus
Cerebrovascular stenosis/occlusion
Acquired encephalocele
Otolaryngology
Conductive hearing loss
Recurrent otitis media
Chronic congestion (poorly pneumatized sinuses)
Rhinorrhea
Choanal atresia
Rhinosinusitis
Obstructive sleep apnea
Hematology
Thrombocytopenia with bleeding
Anemia
Leukopenia with frequent infections
Hepatosplenomegaly
Transfusion dependence
Nephrology
Renal tubular acidosis, nephrocalcinosis, and nephrolithiasis (CAII deficiency)

Screening and Monitoring for patients with Osteopetrosis

Intervention
Timing
Serum calcium
At diagnosis and every 6–12 months (every 3 months during calcitriol therapy)
Serum phosphorus
At diagnosis and every 6–12 months (every 3 months during calcitriol therapy)
Serum creatinine
At diagnosis (every 3 months during calcitriol therapy)
25(OH)D
At diagnosis and every 6–12 months
Parathyroid hormone
At diagnosis and every 6–12 months
Complete blood count with differential
At diagnosis and every 6–12 months
BB isozyme of creatine kinase
At diagnosis
Lactate dehydrogenase
At diagnosis
MRI to evaluate optic nerves
At diagnosis and as clinically indicated
Urinary calcium/creatinine ratio (random or 24 hours)
At initiation of calcitriol and every 3 months during calcitriol therapy
Renal ultrasonography
At diagnosis and every 12 months in patients with CAII mutations (every 12 months during calcitriol therapy)

References